Dyadic International (NASDAQ:DYAI) Shares Pass Below Fifty Day Moving Average – Time to Sell?

Dyadic International, Inc. (NASDAQ:DYAI) shares crossed below its 50-day moving average during trading on Wednesday . The stock has a 50-day moving average of $1.64 and traded as low as $1.55. Dyadic International shares last traded at $1.58, with a volume of 22,184 shares traded.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a “buy” rating and issued a $6.00 target price on shares of Dyadic International in a report on Thursday, November 14th.

Dyadic International Price Performance

The company has a market cap of $46.75 million, a price-to-earnings ratio of -6.87 and a beta of 0.89. The company’s 50 day moving average price is $1.64 and its 200 day moving average price is $1.40. The company has a debt-to-equity ratio of 1.54, a quick ratio of 5.15 and a current ratio of 5.15.

Dyadic International (NASDAQ:DYAI) last posted its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported ($0.01) earnings per share for the quarter, topping the consensus estimate of ($0.07) by $0.06. The company had revenue of $1.96 million during the quarter, compared to analyst estimates of $1.05 million. Dyadic International had a negative net margin of 188.09% and a negative return on equity of 149.16%. During the same quarter last year, the business posted ($0.06) earnings per share. On average, equities research analysts predict that Dyadic International, Inc. will post -0.18 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Dyadic International

An institutional investor recently bought a new position in Dyadic International stock. Truist Financial Corp acquired a new position in Dyadic International, Inc. (NASDAQ:DYAI) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 250,000 shares of the biotechnology company’s stock, valued at approximately $428,000. Truist Financial Corp owned approximately 0.84% of Dyadic International as of its most recent filing with the Securities and Exchange Commission (SEC). 27.95% of the stock is owned by hedge funds and other institutional investors.

Dyadic International Company Profile

Dyadic International, Inc, a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health.